Assessment of therapy for XXXX . The TE Study Group.

@entity1 @entity137 @entity1910 @entity11682 @entity4765 @entity882 @entity1431 @entity3251 @entity3230 @entity1292 @entity288
@entity3251 has been reported as a life-threatening @entity1292 among @entity1 with the acquired @entity3230 . The TE Study Group was established to address clinical questions about @entity3251 by retrospectively reviewing available data. The medical centers selected were those reporting @entity3251 to the Centers for Disease Control or to one of the principal investigators. Sixty-eight histologically confirmed cases of @entity3251 were reported by investigators at 31 medical centers; 61 of the @entity1 received some therapy. Overall prognosis was poor. The median survival following initiation of therapy was four months. @entity1 described as "alert" at initiation of therapy survived significantly longer than those described as "lethargic" or "stuporous." No beneficial or harmful effects could be attributed to the use of @entity288 . @entity137 attributed to @entity4765 and @entity11682 therapy was reported in 60 percent of @entity1 . @entity1431 , @entity1910 , and @entity882 were common during therapy. A clinical relapse of @entity3251 was reported in 50 percent of @entity1 discharged from the hospital.
